10/12/2017
Christie Innomed is pleased to announce the latest FDA approval for its innovative Hologic 3D Mammography™ System — a specially designed tomosynthesis imaging system that enables superior exams for women with higher breast density.
Christie Innomed, the global leader in women’s health imaging technologies, is committed to empowering Canadian healthcare providers to envision more from their suppliers in their delivery of care.
As part of this vision, they are proud to share an approval of their physician labelling by the U.S. Food and Drug Administration (FDA) that recognizes recent clinical acclaim for the Hologic 3D Mammography™. The Hologic 3D Mammography technology offered exclusively in Canada by Christie Innomed is now the only mammogram that is FDA approved as superior to standard 2D mammography for routine breast cancer screening of women with dense breasts.
Detects more invasive breast cancer.
Between 40% and 50% of women ages 40 to 74 have dense breasts. Density is only identifiable on a mammogram or other imaging modalities, and reflects the amount of fibrous or glandular tissue is in the breast. Women with dense breasts often require additional screening, which can result in increased patient anxiety and unnecessary costs. Perhaps most importantly, women with very dense breasts are four to five times more likely to develop breast cancer than women with less dense breasts.
Studies have shown that this exam detects 20% to 65% more invasive breast cancers than 2D mammography alone, with an average increase of 41%.
Christie Innomed’s latest modification for its mammography systems equips the Hologic 2D plus 3D imaging with superior accuracy in screening women with dense breast tissue. Its newly approved labeling is based on clinical studies showing that these modifications to its Hologic’s 3D digital breast tomosynthesis system enhance invasive breast cancer detection, while reducing unnecessary recalls.
As a renowned leader in providing advanced Women’s Health imaging solutions in Canada, this approval reinforces Christie Innomed’s continued dedication to enable healthcare providers to improve detection rates and early treatment for invasive breast cancer.
About Christie Innomed
Established in 1954, Christie Innomed develops, distributes, integrates and supports innovative medical imaging and health information management solutions that improve Canadian healthcare performance.
Christie Innomed is a leading medical imaging distributor with more than 200 dedicated specialists servicing over 1500 hospitals and clinics supported by 8 offices throughout Canada. Our focus is on bringing innovative technologies to Canadian healthcare institutions in the areas of medical imaging, medical informatics and healthcare IT solutions.